Research reporting standards for radioembolization of hepatic malignancies.
作者信息
Salem Riad, Lewandowski Robert J, Gates Vanessa L, Nutting Charles W, Murthy Ravi, Rose Steven C, Soulen Michael C, Geschwind Jean-Francois H, Kulik Laura, Kim Yun Hwan, Spreafico Carlo, Maccauro Marco, Bester Lourens, Brown Daniel B, Ryu Robert K W, Sze Daniel Y, Rilling William S, Sato Kent T, Sangro Bruno, Bilbao Jose Ignacio, Jakobs Tobias F, Ezziddin Samer, Kulkarni Suyash, Kulkarni Aniruddha, Liu David M, Valenti David, Hilgard Philip, Antoch Gerald, Muller Stefan P, Alsuhaibani Hamad, Mulcahy Mary F, Burrel Marta, Real Maria Isabel, Spies Stewart, Esmail Abdulredha A, Raoul Jean-Luc, Garin Etienne, Johnson Mathew S, Benson Al B, Sharma Ricky A, Wasan Harpreet, Lambert Bieke, Memon Khairuddin, Kennedy Andrew S, Riaz Ahsun
机构信息
Department of Radiology and Medical Oncology, Section of Interventional Radiology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
出版信息
J Vasc Interv Radiol. 2011 Mar;22(3):265-78. doi: 10.1016/j.jvir.2010.10.029.
Abstract
摘要
相似文献
1
Research reporting standards for radioembolization of hepatic malignancies.肝恶性肿瘤放射性栓塞治疗的研究报告标准
J Vasc Interv Radiol. 2011 Mar;22(3):265-78. doi: 10.1016/j.jvir.2010.10.029.
2
Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.肝脏恶性肿瘤的放射性栓塞：背景、质量改进指南及未来方向
J Vasc Interv Radiol. 2017 Jan;28(1):1-15. doi: 10.1016/j.jvir.2016.09.024. Epub 2016 Nov 9.
3
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria.经导管肝恶性肿瘤治疗：术语和报告标准的规范化
J Vasc Interv Radiol. 2016 Apr;27(4):457-73. doi: 10.1016/j.jvir.2015.12.752. Epub 2016 Feb 2.
4
Invited commentary.特邀评论。
J Vasc Interv Radiol. 2011 Oct;22(10):1362-3. doi: 10.1016/j.jvir.2011.07.013.
5
Ruptured Hepatocellular Carcinoma following Transarterial Radioembolization.经动脉放射性栓塞术后肝细胞癌破裂
J Vasc Interv Radiol. 2018 Sep;29(9):1302-1305. doi: 10.1016/j.jvir.2018.04.017.
6
Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres.在用玻璃微球进行放射性栓塞之前，通常无需对胃十二指肠动脉和胃右动脉进行预防性栓塞。
J Vasc Interv Radiol. 2013 Nov;24(11):1743-5. doi: 10.1016/j.jvir.2013.07.011.
7
Yttrium-90 Radioembolization for Breast Cancer Liver Metastases.钇-90放射性栓塞治疗乳腺癌肝转移
J Vasc Interv Radiol. 2016 Sep;27(9):1316-1319. doi: 10.1016/j.jvir.2016.06.016.
8
Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.钇-90放射性栓塞治疗不可切除肝转移瘤患者：确定影响治疗效果的因素
Hepatogastroenterology. 2014 Sep;61(134):1529-34.
9
Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.肝脏钇-90 放射性栓塞治疗转移性黑色素瘤：单中心经验。
Melanoma Res. 2014 Jun;24(3):244-51. doi: 10.1097/CMR.0000000000000051.
10
Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.钇-90微球放射性栓塞治疗胰腺腺癌肝转移：一项多中心分析
J Vasc Interv Radiol. 2019 Mar;30(3):298-304.e2. doi: 10.1016/j.jvir.2018.09.020.
引用本文的文献
1
Comparison of Dosimetry Models and Dose Thresholds for Predicting Pathologic Response to Yttrium-90 Radioembolization with Glass Microspheres.用于预测钇-90玻璃微球放射性栓塞病理反应的剂量测定模型和剂量阈值的比较
Cardiovasc Intervent Radiol. 2025 Aug 20. doi: 10.1007/s00270-025-04161-0.
2
Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.选择性内放射治疗联合免疫检查点抑制剂治疗肝细胞癌：一项系统评价和单臂荟萃分析
Dig Dis Sci. 2025 Jun 26. doi: 10.1007/s10620-025-09139-z.
3
Musculoskeletal abscopal effect: a review of the important imaging findings and their clinical relevance.肌肉骨骼远隔效应：重要影像学表现及其临床相关性综述
Skeletal Radiol. 2025 May 15. doi: 10.1007/s00256-025-04944-z.
4
Health Outcomes and Resource Consumption Analysis of Radioembolization with Y90 Glass Microspheres (TARE-Y90) Versus Transarterial Chemoembolization with Irinotecan (DEBIRI) in Patients with Liver Metastases from Colorectal Cancer in Spain.西班牙结直肠癌肝转移患者中，钇90玻璃微球放射性栓塞（TARE-Y90）与伊立替康经动脉化疗栓塞（DEBIRI）的健康结局与资源消耗分析
Diagnostics (Basel). 2025 Mar 21;15(7):796. doi: 10.3390/diagnostics15070796.
5
Insights into handling and delivery of Y-90 radioembolization therapies.Y-90放射性栓塞治疗的操作与递送见解。
Front Nucl Med. 2023 Mar 21;3:1075782. doi: 10.3389/fnume.2023.1075782. eCollection 2023.
6
Predictive Value of [Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [Y]-TARE: A Single-Center Experience.基于[Tc]-MAA的剂量测定法在接受[Y]-TARE治疗的肝细胞癌患者中的预测价值：单中心经验
Diagnostics (Basel). 2023 Jul 20;13(14):2432. doi: 10.3390/diagnostics13142432.
7
Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review.钇[90Y]微球放射性栓塞治疗结直肠癌肝转移的经济学评价：系统评价。
BMC Gastroenterol. 2023 May 24;23(1):181. doi: 10.1186/s12876-023-02793-5.
8
Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances.作为治疗性栓塞程序载体系统的微球：成就与进展
J Clin Med. 2023 Jan 24;12(3):918. doi: 10.3390/jcm12030918.
9
Simplification of dosimetry in Y-radioembolization therapy by dual planar images.通过双平面图像简化 Y 放射性栓塞治疗中的剂量学。
BMC Cancer. 2022 Dec 8;22(1):1288. doi: 10.1186/s12885-022-10392-y.
10
Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score.肝内胆管癌患者的经动脉钇-90放射性栓塞：应用预后评分进行疗效评估
Cancers (Basel). 2022 Oct 29;14(21):5324. doi: 10.3390/cancers14215324.
本文引用的文献
1
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.单独或联合使用 EASL、RECIST 和 WHO 反应指南在肝细胞癌中的作用：放射病理相关性。
J Hepatol. 2011 Apr;54(4):695-704. doi: 10.1016/j.jhep.2010.10.004. Epub 2010 Oct 23.
2
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.与化疗栓塞相比，放射性栓塞可使肝癌患者的疾病进展时间延长且毒性降低。
Gastroenterology. 2011 Feb;140(2):497-507.e2. doi: 10.1053/j.gastro.2010.10.049. Epub 2010 Oct 30.
3
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.放射性节段切除术：一种提高放射性栓塞安全性和疗效的新方法。
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):163-71. doi: 10.1016/j.ijrobp.2009.10.062. Epub 2010 Apr 24.
4
Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.放射性栓塞术（钇 90 微球）治疗原发性和转移性肝恶性肿瘤。
Cancer J. 2010 Mar-Apr;16(2):163-75. doi: 10.1097/PPO.0b013e3181d7e8cf.
5
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.经肝动脉区域性治疗原发性肝癌的影像反应与临床结果。
JAMA. 2010 Mar 17;303(11):1062-9. doi: 10.1001/jama.2010.262.
6
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.改良版 RECIST（mRECIST）用于肝细胞癌的评估。
Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
7
Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy.基于小叶微解剖的 (90)Y 微球治疗中肝脏结构剂量学：蒙特卡罗建模方法。
J Nucl Med. 2010 Feb;51(2):301-10. doi: 10.2967/jnumed.109.069278. Epub 2010 Jan 15.
8
Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.钇-90 放射性栓塞治疗晚期肝细胞癌的预后因素分析。
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1441-8. doi: 10.1016/j.ijrobp.2009.07.006. Epub 2010 Jan 7.
9
Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors.肝肿瘤放射性栓塞治疗前肝内血管闭塞再分配血流的安全性和有效性评估。
Cardiovasc Intervent Radiol. 2010 Jun;33(3):523-31. doi: 10.1007/s00270-009-9717-1. Epub 2009 Oct 20.
10
First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.钇-90（TheraSphere）微球标记肝动脉内放射性栓塞治疗的初步经验：实施方面的实际问题。
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):453-61. doi: 10.1007/s00259-009-1279-6. Epub 2009 Oct 10.
Zotero 插件